Alpine Immune Sciences, Inc. announced that Natasha A. Hernday has joined Alpine’s Board of Directors. Ms. Hernday brings more than 20 years of experience in corporate development and corporate strategy. Ms. Hernday currently serves as Executive Vice President, Corporate Development and as a member of the Executive Committee for the publicly traded biotechnology company Seagen, Inc. Since joining Seagen in 2011, Ms. Hernday has built and led the business development team responsible for licensing deals, acquisitions and strategic alliances. Concurrent with Ms. Hernday joining Alpine’s Board of Directors, the company also announced that Paul Sekhri will be stepping down as a director of the company. Mr. Sekhri has served on Alpine’s Board of Directors since February 2016.